In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 2213-63-0, name is 2,3-Dichloroquinoxaline, introducing its new discovery. Product Details of 2213-63-0
The present invention provides a process for efficiently producing an alkylated aromatic compound in good yield, by a cross-coupling reaction between an alkyl halide and an aromatic magnesium reagent. A process for producing an aromatic compound represented by Formula (1): R?Ar???(1) wherein R is a hydrocarbon group, and Ar? is an aryl group; the process comprising: reacting a compound represented by Formula (2): R?X??(2) wherein X is a halogen atom, and R is as defined above, with a magnesium reagent represented by Formula (3): Ar??MgY??(3) wherein Y is a halogen atom, and Ar? is as defined above, in the presence of a catalyst for cross-coupling reactions comprising an iron compound and a bisphosphine compound represented by Formula (4): wherein Q is a divalent group derived from an aromatic ring by removing two hydrogen (H) atoms on adjacent carbon atoms; and each Ar is independently an aryl group.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 2213-63-0, and how the biochemistry of the body works.Product Details of 2213-63-0
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1174 | ChemSpider